List of Vibativ drug patents

Vibativ is owned by Cumberland Pharms.

Vibativ contains Telavancin Hydrochloride.

Vibativ has a total of 3 drug patents out of which 1 drug patent has expired.

Expired drug patents of Vibativ are:

  • US6858584

Vibativ was authorised for market use on 11 September, 2009.

Vibativ is available in powder;intravenous dosage forms.

Vibativ can be used as method for treating bacterial infection.

The generics of Vibativ are possible to be released after 01 January, 2027.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6635618 CUMBERLAND PHARMS Glycopeptide phosphonate derivatives
Sep, 2023

(7 months from now)

US7531623 CUMBERLAND PHARMS Hydrochloride salts of a glycopeptide phosphonate derivative
Jan, 2027

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6858584 CUMBERLAND PHARMS Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin
Aug, 2022

(5 months ago)

Drugs and Companies using TELAVANCIN HYDROCHLORIDE ingredient

Market Authorisation Date: 11 September, 2009

Treatment: Method for treating bacterial infection

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in